Literature DB >> 2651096

The posttranslational processing of prodynorphin in the rat anterior pituitary.

R Day1, H Akil.   

Abstract

The posttranslational processing of prodynorphin (Pro-Dyn) is not well understood. The rat anterior pituitary is an interesting tissue which merits examination to address this issue since it is known that Dyn immunoreactivity is stored as high mol wt (HMW) intermediates and not as free products such as dynorphin-A-(1-17) (Dyn-A17) or dynorphin-B-(1-13) (Dyn-B). The aim of our study is to characterize the Pro-Dyn products in the rat anterior pituitary quantitatively as well as qualitatively by keeping a close account of each of the possible domains that are known to compose the protein structure. This was achieved by a convergence of tools: designing RIA with antibodies to each of these domains, including antibodies to Dyn-A17, Dyn-B, alpha-neo-endorphin, bridge peptide, and Pro-Dyn carboxyl-terminal peptide (C-peptide), and using these antisera with gel filtration chromatography, reverse phase HPLC, immunoaffinity, and immunoprecipitation techniques. Our data indicate the presence of at least six distinct molecules which are classified as HMW intermediates (greater than 3.5K). By gel filtration chromatography they have apparent mol wt of 16,000, 10,000, 8,000, 6,000, 4,000, and 3,500, respectively. Each of these structures is characterized by multiple immunoreactivities to account for the observed mass. Based on the relative content of each structure we present a scheme for the posttranslational processing pathway of Pro-Dyn in the rat anterior pituitary. We also analyze other tissues, spinal cord and hypothalamus, for their content of Pro-Dyn HMW intermediates. Our results indicate that these tissues store Pro-Dyn HMW molecules of similar sizes and immunoreactive properties, suggesting that Pro-Dyn may be processed in a similar manner, at least in the initial phases, across tissues.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2651096     DOI: 10.1210/endo-124-5-2392

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

Review 1.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

Review 2.  Towards a functional significance of peptides and biogenic amines produced by the anterior pituitary.

Authors:  H Houben; D Tilemans; C Denef
Journal:  J Endocrinol Invest       Date:  1990-11       Impact factor: 4.256

3.  Dynorphin peptides differentially regulate the human kappa opioid receptor.

Authors:  Yong Chen; Chongguang Chen; Lee-Yuan Liu-Chen
Journal:  Life Sci       Date:  2007-01-20       Impact factor: 5.037

4.  Identification and characterization of novel PDYN mutations in dominant cerebellar ataxia cases.

Authors:  Justyna Jezierska; Giovanni Stevanin; Hiroyuki Watanabe; Michiel R Fokkens; Fabien Zagnoli; Jérôme Kok; Jean-Yves Goas; Pierre Bertrand; Christophe Robin; Alexis Brice; Georgy Bakalkin; Alexandra Durr; Dineke S Verbeek
Journal:  J Neurol       Date:  2013-03-08       Impact factor: 4.849

5.  Atypical prodynorphin gene expression in corticosteroid-producing cells of the rat adrenal gland.

Authors:  R Day; M K Schafer; M W Collard; S J Watson; H Akil
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

6.  Considerations on Using Antibodies for Studying the Dynorphins/Kappa Opioid Receptor System.

Authors:  Chongguang Chen; Melanie Widmann; Christoph Schwarzer; Lee-Yuan Liu-Chen
Journal:  Handb Exp Pharmacol       Date:  2022
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.